OpenLB
Open Library of Bioscience
Advanced Search
PeerJ
2025;13 e19188.

MicroRNA-99 family in cancer: molecular mechanisms for clinical applications.

Yueyuan Wang, Dan Huang, Mingxi Li, Ming Yang
Author Information
  1. Yueyuan Wang: Department of Breast Surgery, General Surgery Center, The First Hospital of Jilin University, ChangChun, Jilin, China.
  2. Dan Huang: Department of Breast Surgery, General Surgery Center, The First Hospital of Jilin University, ChangChun, Jilin, China.
  3. Mingxi Li: Department of Neurology and Neuroscience Center, The First Hospital of Jilin University, ChangChun, Jilin, China.
  4. Ming Yang: Department of Breast Surgery, General Surgery Center, The First Hospital of Jilin University, ChangChun, Jilin, China.
PMID: 40161350 DOI: 10.7717/peerj.19188

Abstract

MicroRNAs (miRNAs) are a class of non-coding RNA sequences that regulate gene expression post-transcriptionally. The miR-99 family, which is highly evolutionarily conserved, comprises three homologs: miR-99a, miR-99b, and miR-100. Its members are under-expressed in most cancerous tissues, suggesting their cancer-repressing properties in multiple cancers; however, in some contexts, they also promote malignant lesion progression. MiR-99 family members target numerous genes involved in various tumor-related processes such as tumorigenesis, proliferation, cell-cycle regulation, apoptosis, invasion, and metastasis. We review the recent research on this family, summarize its implications in cancer, and explore its potential as a biomarker and cancer therapeutic target. This review contributes to the clinical translation of the miR-99 family members.

Keywords

Biomarker Cancer Resistance miR-99

References

Bull Exp Biol Med. 2019 Mar;166(5):641-645 [PMID: 30903488]
Trends Cell Biol. 2008 Oct;18(10):505-16 [PMID: 18774294]
BMC Cancer. 2023 Aug 15;23(1):755 [PMID: 37582734]
Am J Transl Res. 2016 Feb 15;8(2):1082-90 [PMID: 27158394]
Cancer Lett. 2019 Jul 10;454:134-145 [PMID: 30981762]
Nat Med. 2017 Nov;23(11):1331-1341 [PMID: 29035371]
Sci Rep. 2017 Jun 22;7(1):4079 [PMID: 28642484]
Mol Med Rep. 2016 Jun;13(6):4549-60 [PMID: 27081843]
Genes (Basel). 2020 Sep 08;11(9): [PMID: 32911741]
Cancer Res. 2010 Jun 1;70(11):4666-75 [PMID: 20484036]
Cell Death Dis. 2019 Jun 4;10(6):437 [PMID: 31164632]
Comput Biol Med. 2023 Mar;155:106598 [PMID: 36764156]
Oncol Lett. 2022 May 27;24(1):228 [PMID: 35720506]
Cell Death Dis. 2020 Mar 9;11(3):176 [PMID: 32152275]
J Exp Clin Cancer Res. 2020 Nov 17;39(1):246 [PMID: 33198772]
Breast Cancer Res Treat. 2012 Jul;134(1):41-51 [PMID: 22167321]
Oncol Rep. 2016 Dec;36(6):3552-3558 [PMID: 27748936]
Cancer Med. 2023 Jul;12(13):14468-14483 [PMID: 37184125]
Int J Oncol. 2014 Jul;45(1):362-72 [PMID: 24805183]
Blood Adv. 2017 May 04;1(12):733-747 [PMID: 29296717]
Neoplasma. 2016;63(5):799-808 [PMID: 27468885]
J Pathol. 2016 Dec;240(4):450-460 [PMID: 27577856]
Mol Cancer. 2014 Jan 10;13:6 [PMID: 24410957]
J Immunol Res. 2021 Jul 17;2021:9920786 [PMID: 34337085]
Oncogene. 2016 Jun 30;35(26):3376-86 [PMID: 26455324]
Cancer Cell Int. 2019 Dec 27;19:354 [PMID: 31889906]
BMC Urol. 2014 Jun 23;14:50 [PMID: 24957100]
Nucleic Acids Res. 2018 Jan 9;46(1):71-82 [PMID: 29165639]
Cancer Manag Res. 2020 Jun 02;12:4129-4137 [PMID: 32606920]
Clin Transl Sci. 2022 Feb;15(2):567-575 [PMID: 32356935]
Oncol Rep. 2012 Apr;27(4):1238-44 [PMID: 22246341]
Cancer Biomark. 2018;22(1):101-110 [PMID: 29630523]
NPJ Breast Cancer. 2022 Oct 29;8(1):115 [PMID: 36309503]
CNS Neurosci Ther. 2022 Jun;28(6):897-912 [PMID: 35212145]
Exp Mol Med. 2023 Jul;55(7):1314-1321 [PMID: 37430087]
Anal Chem. 2024 Dec 10;96(49):19670-19677 [PMID: 39613483]
Onco Targets Ther. 2019 Nov 27;12:10311-10321 [PMID: 31819515]
Oncogene. 2017 Feb 23;36(8):1023-1037 [PMID: 27524417]
EMBO Rep. 2007 Aug;8(8):763-9 [PMID: 17599088]
J Cancer. 2020 Feb 10;11(9):2485-2495 [PMID: 32201519]
Cancer Commun (Lond). 2022 Dec;42(12):1412-1416 [PMID: 35997029]
Genome Res. 2009 Jan;19(1):92-105 [PMID: 18955434]
Genome Res. 2017 Jul;27(7):1112-1125 [PMID: 28411194]
Hematology. 2023 Dec;28(1):2196857 [PMID: 37014739]
CA Cancer J Clin. 2024 May-Jun;74(3):229-263 [PMID: 38572751]
Front Oncol. 2020 Dec 01;10:578948 [PMID: 33335853]
BMC Cancer. 2012 Aug 24;12:369 [PMID: 22920721]
Cancer Lett. 2012 Apr 28;317(2):184-91 [PMID: 22120675]
J Int Med Res. 2021 May;49(5):300060520939031 [PMID: 34038200]
Cancer Biomark. 2017 Dec 6;20(4):527-537 [PMID: 28800315]
Mol Med Rep. 2015 Apr;11(4):2947-52 [PMID: 25483280]
Clin Transl Med. 2017 Oct 4;6(1):37 [PMID: 28980224]
Theranostics. 2017 Jan 15;7(3):677-693 [PMID: 28255359]
J Clin Lab Anal. 2022 Jan;36(1):e24168 [PMID: 34888946]
Clin Transl Med. 2021 Sep;11(9):e545 [PMID: 34586732]
Oncol Rep. 2016 Jun;35(6):3453-9 [PMID: 27035873]
Front Oncol. 2022 Feb 11;11:795242 [PMID: 35223454]
Cancer Sci. 2018 Oct;109(10):3326-3335 [PMID: 30022565]
Nature. 2010 Feb 25;463(7284):1084-8 [PMID: 20118916]
Oncol Rep. 2014 May;31(5):2055-62 [PMID: 24626817]
Mol Cell Biochem. 2025 Feb;480(2):1001-1012 [PMID: 38720056]
Neuroreport. 2021 Jun 9;32(9):748-756 [PMID: 33994521]
Adv Sci (Weinh). 2023 Aug;10(24):e2300452 [PMID: 37357137]
Cancer Cell Int. 2021 Dec 15;21(1):674 [PMID: 34911544]
Oncogene. 2014 Mar 13;33(11):1448-57 [PMID: 23503464]
Mol Cancer Res. 2020 Feb;18(2):287-299 [PMID: 31694930]
Stem Cell Rev Rep. 2023 Nov;19(8):2901-2917 [PMID: 37653181]
Cancer Sci. 2017 Mar;108(3):390-397 [PMID: 28032929]
Int J Cancer. 2010 May 1;126(9):2036-48 [PMID: 19739117]
Leukemia. 2010 Jan;24(1):89-96 [PMID: 19890372]
Oncol Lett. 2018 Oct;16(4):5355-5360 [PMID: 30250606]
Cancers (Basel). 2023 Apr 14;15(8): [PMID: 37190222]
Pharmgenomics Pers Med. 2020 Aug 10;13:283-288 [PMID: 32848443]
Oncol Rep. 2016 May;35(5):2755-66 [PMID: 26986073]
PLoS One. 2014 Mar 20;9(3):e92292 [PMID: 24651474]
PLoS One. 2014 Mar 17;9(3):e92099 [PMID: 24637915]
Biol Chem. 2019 Jul 09;400(8):1079-1086 [PMID: 31287793]
DNA Repair (Amst). 2010 Nov 10;9(11):1170-5 [PMID: 20869334]
Front Oncol. 2023 Nov 07;13:1184186 [PMID: 38023145]
PLoS One. 2013 Nov 14;8(11):e80865 [PMID: 24244722]
Mol Biotechnol. 2022 Nov;64(11):1234-1243 [PMID: 35532870]
Leuk Res. 2012 Mar;36(3):293-8 [PMID: 22099053]
Int J Pharm. 2022 Nov 5;627:122214 [PMID: 36152993]
Biomed Pharmacother. 2019 Jan;109:788-797 [PMID: 30551532]
J Clin Invest. 2018 Dec 3;128(12):5505-5516 [PMID: 30260323]
Cancer Cell. 2015 Jan 12;27(1):41-56 [PMID: 25584893]
Oncogene. 2011 Aug 11;30(32):3489-501 [PMID: 21383697]
Am J Transl Res. 2016 Feb 15;8(2):719-31 [PMID: 27158364]
Int Urol Nephrol. 2023 Oct;55(10):2483-2491 [PMID: 37338656]
Urol Oncol. 2011 May-Jun;29(3):265-9 [PMID: 19372056]
J Hematol Oncol. 2013 Jan 15;6:6 [PMID: 23321005]
Oncogene. 2013 Jul 4;32(27):3306-10 [PMID: 22926517]
Int J Cancer. 2019 Jun 1;144(11):2774-2781 [PMID: 30478850]
Int J Mol Sci. 2017 Dec 07;18(12): [PMID: 29215599]
Biochem Biophys Res Commun. 2019 Apr 2;511(2):260-265 [PMID: 30791979]
Front Genet. 2019 Mar 29;10:280 [PMID: 30984249]
Oncogene. 2012 Jan 5;31(1):80-92 [PMID: 21643017]
Infect Agent Cancer. 2022 Jan 3;17(1):1 [PMID: 34980191]
Med Oncol. 2014 May;31(5):934 [PMID: 24668416]
Cancer Lett. 2015 Dec 28;369(2):376-85 [PMID: 26404754]
Tumour Biol. 2016 Apr;37(4):5001-11 [PMID: 26537584]
Nature. 2022 Jan;601(7893):446-451 [PMID: 34937935]
Cancer Cell Int. 2023 Sep 9;23(1):199 [PMID: 37689710]
Cancer. 2014 Dec 1;120(23):3635-41 [PMID: 25091571]
Dev Cell. 2006 Oct;11(4):441-50 [PMID: 17011485]
PLoS One. 2013;8(2):e55652 [PMID: 23409016]
Mol Cancer. 2014 Jul 15;13:171 [PMID: 25027842]
Mol Cancer. 2006 Jun 19;5:24 [PMID: 16784538]
Mediators Inflamm. 2016;2016:5308170 [PMID: 27403035]
Exp Ther Med. 2012 Jan;3(1):149-153 [PMID: 22969861]
Nucl Med Commun. 2014 Sep;35(9):932-8 [PMID: 24785011]
Int J Biol Sci. 2016 Nov 5;12(12):1437-1447 [PMID: 27994509]
Int J Mol Sci. 2018 Apr 27;19(5): [PMID: 29702599]
Biomed J. 2021 Dec;44(6 Suppl 2):S305-S315 [PMID: 35307327]
Gene. 2019 May 25;698:141-149 [PMID: 30849536]
Front Oncol. 2020 Jan 24;9:1473 [PMID: 32038996]
Protein Pept Lett. 2022;29(10):829-838 [PMID: 35794743]
Haematologica. 2022 Jan 01;107(1):100-111 [PMID: 34134471]
Int J Mol Sci. 2020 Oct 02;21(19): [PMID: 33023154]
Int J Mol Sci. 2020 Jun 29;21(13): [PMID: 32610706]
Front Endocrinol (Lausanne). 2018 Aug 03;9:402 [PMID: 30123182]
Cells. 2021 Jul 22;10(8): [PMID: 34440625]
Arch Med Sci. 2020 Oct 13;19(3):694-702 [PMID: 37313204]
Gut Liver. 2015 Mar;9(2):188-96 [PMID: 25167801]
Oncol Lett. 2020 Aug;20(2):1336-1344 [PMID: 32724376]
Braz J Med Biol Res. 2018 Aug 16;51(10):e6839 [PMID: 30156609]
J Biol Chem. 2011 Oct 21;286(42):36677-85 [PMID: 21878637]
Acta Biochim Biophys Sin (Shanghai). 2021 Dec 8;53(12):1650-1661 [PMID: 34687203]
Cancers (Basel). 2022 Jul 20;14(14): [PMID: 35884594]
Cancer Biol Ther. 2014 Oct;15(10):1423-30 [PMID: 25046358]
Nucleic Acids Res. 2014 Apr;42(8):5245-55 [PMID: 24561617]
Br J Cancer. 2015 Aug 11;113(4):634-44 [PMID: 26196183]
J Exp Med. 2017 Aug 7;214(8):2453-2470 [PMID: 28733386]
J Pathol Clin Res. 2023 Sep;9(5):354-366 [PMID: 37246239]
Oncol Res. 2020 Sep 1;28(4):385-398 [PMID: 32252875]
RNA. 2005 Mar;11(3):241-7 [PMID: 15701730]
Lancet Oncol. 2010 Feb;11(2):136-46 [PMID: 20022810]
World J Surg Oncol. 2021 Jul 4;19(1):199 [PMID: 34218800]
Biomolecules. 2022 May 11;12(5): [PMID: 35625614]
Cancer Discov. 2012 May;2(5):401-4 [PMID: 22588877]
Med Oncol. 2013 Mar;30(1):411 [PMID: 23292834]
Cancer Biomark. 2018;23(3):333-339 [PMID: 30223386]
Oncol Lett. 2021 Dec;22(6):816 [PMID: 34671430]
Mol Med Rep. 2015 Feb;11(2):1469-75 [PMID: 25352177]
Genes Dev. 2014 Apr 15;28(8):858-74 [PMID: 24736844]
Cancer Med. 2023 Sep;12(17):18005-18019 [PMID: 37496297]
Wiley Interdiscip Rev RNA. 2021 May;12(3):e1635 [PMID: 33230974]
J Surg Oncol. 2013 Sep;108(4):248-55 [PMID: 23893385]
Biomed Pharmacother. 2018 May;101:656-662 [PMID: 29518612]
Cancer Res. 2007 Jul 1;67(13):6031-43 [PMID: 17616659]
Oncol Lett. 2019 Aug;18(2):1318-1322 [PMID: 31423192]
Biomaterials. 2019 Oct;218:119342 [PMID: 31326657]
Aging (Albany NY). 2024 Feb 29;16(5):4224-4235 [PMID: 38431286]
Pancreas. 2012 Jul;41(5):685-90 [PMID: 22466166]
Oncol Rep. 2014 Oct;32(4):1409-18 [PMID: 25109390]
Cells. 2019 Nov 28;8(12): [PMID: 31795200]
Sci Rep. 2023 Dec 6;13(1):21544 [PMID: 38057448]
Front Oncol. 2020 Sep 18;10:1495 [PMID: 33072545]
Int Immunopharmacol. 2024 Dec 5;142(Pt B):113168 [PMID: 39298813]
Mol Cancer. 2022 Mar 12;21(1):74 [PMID: 35279145]
J Surg Res. 2014 Dec;192(2):515-20 [PMID: 25218280]
Int J Oncol. 2015 Oct;47(4):1528-36 [PMID: 26315788]
Cell Biol Int. 2017 Dec;41(12):1345-1355 [PMID: 28816390]
Oncogene. 2011 Apr 21;30(16):1956-62 [PMID: 21151178]
Br J Cancer. 2013 Oct 15;109(8):2189-98 [PMID: 24030073]
Biochem Biophys Res Commun. 2020 Feb 19;522(4):855-861 [PMID: 31801665]
Bioengineered. 2022 Feb;13(2):2004-2016 [PMID: 35030978]
Biomed Pharmacother. 2020 Jun;126:110085 [PMID: 32199224]
Cell. 2007 Jun 29;129(7):1401-14 [PMID: 17604727]
Cells. 2020 Sep 11;9(9): [PMID: 32932948]
Nucleic Acids Res. 2015 Sep 18;43(16):8057-65 [PMID: 26209130]
J Clin Invest. 2013 Feb;123(2):855-65 [PMID: 23298836]
Cell Biol Toxicol. 2021 Aug;37(4):633-651 [PMID: 33400021]
Oncogenesis. 2018 Dec 19;7(12):97 [PMID: 30563983]
Am J Cancer Res. 2024 Jan 15;14(1):114-129 [PMID: 38323281]
J Hum Genet. 2021 May;66(5):519-534 [PMID: 33177704]
Thorac Cancer. 2020 Jun;11(6):1679-1688 [PMID: 32364673]
Int J Mol Sci. 2020 Oct 08;21(19): [PMID: 33050096]
PLoS One. 2018 Nov 2;13(11):e0206542 [PMID: 30388154]
Cancers (Basel). 2024 May 19;16(10): [PMID: 38792011]
Cancer Res. 2011 Feb 15;71(4):1313-24 [PMID: 21212412]
Mol Med Rep. 2012 Sep;6(3):675-81 [PMID: 22751686]
Cell. 2005 Jan 14;120(1):15-20 [PMID: 15652477]
Cancers (Basel). 2021 Oct 22;13(21): [PMID: 34771465]
Adv Ther (Weinh). 2022 Aug;5(8): [PMID: 36212523]
Mol Oncol. 2022 Mar;16(6):1329-1346 [PMID: 35148461]
Cell Prolif. 2014 Dec;47(6):587-95 [PMID: 25348507]
Cancer Lett. 2018 Jul 28;427:38-48 [PMID: 29679612]
J Cell Physiol. 2019 Apr;234(4):3526-3537 [PMID: 30443946]
PLoS One. 2012;7(1):e31032 [PMID: 22299047]
Cell Signal. 2015 Jun;27(6):1087-101 [PMID: 25703026]
Head Neck. 2019 Oct;41(10):3499-3515 [PMID: 31355988]
Onco Targets Ther. 2015 Nov 17;8:3391-400 [PMID: 26604796]
Open Med (Wars). 2022 Jul 06;17(1):1172-1182 [PMID: 35859793]
Mol Med Rep. 2010 May-Jun;3(3):387-92 [PMID: 21472251]
Dev Cell. 2003 Aug;5(2):351-8 [PMID: 12919684]
FASEB J. 2021 Feb;35(2):e21193 [PMID: 33205517]
Sci Rep. 2018 Jul 4;8(1):10119 [PMID: 29973668]
Onco Targets Ther. 2020 Jan 20;13:593-602 [PMID: 32021301]
Eur J Cancer. 2014 May;50(8):1541-54 [PMID: 24559685]
Int J Mol Sci. 2022 Aug 25;23(17): [PMID: 36077039]
PLoS Genet. 2014 Feb 27;10(2):e1004177 [PMID: 24586203]
Science. 2007 Dec 21;318(5858):1931-4 [PMID: 18048652]
Cell Death Dis. 2021 Apr 30;12(5):424 [PMID: 33931593]
J Cell Biochem. 2015 Feb;116(2):268-76 [PMID: 25187230]
Biomed Pharmacother. 2019 Sep;117:109151 [PMID: 31229921]
Cancer Lett. 2017 Jul 10;398:37-45 [PMID: 28408353]
J Physiol Biochem. 2023 Feb;79(1):19-34 [PMID: 35984620]
Oncol Lett. 2018 Jan;15(1):453-458 [PMID: 29422961]
J Biol Res (Thessalon). 2020 Nov 11;27:16 [PMID: 33194849]
Mol Cancer Ther. 2013 Feb;12(2):207-19 [PMID: 23270926]
J Immunother Cancer. 2020 Sep;8(2): [PMID: 32948650]
Nat Genet. 2008 Jan;40(1):43-50 [PMID: 18066065]
Nat Commun. 2018 May 10;9(1):1845 [PMID: 29748571]
J Cancer. 2022 Jan 1;13(1):184-201 [PMID: 34976182]
J Urol. 2012 Nov;188(5):1951-6 [PMID: 22999546]
BMC Urol. 2017 Dec 04;17(1):113 [PMID: 29202733]
Urol Oncol. 2013 Aug;31(6):796-801 [PMID: 21880514]
Oncol Lett. 2019 Jun;17(6):5108-5114 [PMID: 31186723]
Ann Thorac Surg. 2011 May;91(5):1523-30 [PMID: 21420070]
Oncogene. 2013 Feb 28;32(9):1164-72 [PMID: 22525276]
PLoS One. 2015 Nov 25;10(11):e0143755 [PMID: 26606261]
Sci Rep. 2020 Dec 8;10(1):21412 [PMID: 33293585]
Leuk Res. 2017 Aug;59:32-40 [PMID: 28544907]
Biomed Pharmacother. 2014 Mar;68(2):163-9 [PMID: 24456664]
J Cell Biochem. 2019 Dec;120(12):19330-19337 [PMID: 30560585]
Mol Ther. 2022 Mar 2;30(3):1119-1134 [PMID: 34998954]
Sci Rep. 2017 Apr 07;7:46250 [PMID: 28387375]
PLoS One. 2013 Jun 10;8(6):e64924 [PMID: 23762265]
Funct Integr Genomics. 2023 Mar 30;23(2):111 [PMID: 36995552]
Proc Natl Acad Sci U S A. 2015 Jun 30;112(26):E3355-64 [PMID: 26080425]
Int J Oncol. 2019 May;54(5):1759-1770 [PMID: 30816432]
BMC Cancer. 2012 Nov 23;12:546 [PMID: 23173671]
Oral Dis. 2014 Apr;20(3):e65-75 [PMID: 23731011]
Cancer Cell Int. 2013 Nov 05;13(1):110 [PMID: 24191888]
Mol Med Rep. 2017 Oct;16(4):5023-5030 [PMID: 28765937]
Mol Cell Biochem. 2013 Nov;383(1-2):49-58 [PMID: 23842624]
Cancer Cell Int. 2022 Apr 27;22(1):165 [PMID: 35477450]
Oncol Lett. 2015 Mar;9(3):1128-1134 [PMID: 25663868]
BMC Cancer. 2018 Nov 5;18(1):1065 [PMID: 30396333]
Mol Cancer. 2018 Jan 12;17(1):6 [PMID: 29329543]
Br J Cancer. 2013 Jul 9;109(1):50-9 [PMID: 23778527]
Mol Cancer. 2013 Jul 25;12:81 [PMID: 23886294]
Cell Death Dis. 2017 Oct 26;8(10):e3141 [PMID: 29072692]
Comb Chem High Throughput Screen. 2024;27(2):214-226 [PMID: 36927435]
Infect Genet Evol. 2019 Sep;73:444-449 [PMID: 31176032]
PLoS One. 2011;6(7):e22484 [PMID: 21811619]
Oncol Lett. 2018 Jun;15(6):8333-8338 [PMID: 29805566]
Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820960748 [PMID: 32945237]
Am J Cancer Res. 2022 Oct 15;12(10):4840-4852 [PMID: 36381329]
Oral Oncol. 2012 Aug;48(8):686-91 [PMID: 22425712]
Int J Nanomedicine. 2017 May 15;12:3721-3733 [PMID: 28553110]
BMC Cancer. 2012 Nov 14;12:519 [PMID: 23151088]
J Invest Dermatol. 2021 Dec;141(12):2944-2956.e6 [PMID: 34186058]
Oncogene. 2012 Oct 18;31(42):4517-26 [PMID: 22249248]

MeSH Term

Humans
MicroRNAs
Neoplasms
Gene Expression Regulation, Neoplastic
Apoptosis
Biomarkers, Tumor
Carcinogenesis

Chemicals

MicroRNAs
MIRN99 microRNA, human
Biomarkers, Tumor
Journal Article Review

Word Cloud

Similar Articles

Cited By